Mark Perry – President & Chief Executive Officer
Mr Perry was appointed as President and Chief Executive Officer of Aerovance effective February 1st, 2007. He has served as a Director since October 2004, and served as Chairman from 2006-2007. Mr Perry was the Senior Business Advisor for Gilead Sciences, Inc., reporting to the CEO. Mr. Perry was an executive officer of Gilead from 1994 to 2004, serving in a variety of capacities, including General Counsel, Chief Financial Officer and most recently, Executive Vice President of Operations, responsible for worldwide sales & marketing, legal, manufacturing and facilities. From 1981 to 1994, Mr. Perry was with the law firm Cooley Godward LLP in San Francisco and Palo Alto, serving as a partner of the firm from 1987 until 1994. Mr. Perry received his J.D. degree from the University of California, Davis in 1980 and is a member of the California bar. Mr. Perry also serves on the Board of Directors of Nuvelo, Inc and Nvidia Corporation.
back to
the top
Richard
Fuller, M.D., Ph.D. – Executive Vice President, Research & Development
Previous Organizations: GSK, Wellcome Trust,
Imperial College London
Previous Products: Flonase®,
Flovent®, Advair®, Serevent®
Dr. Fuller is a Fellow of the Royal College of Physicians
and is clinically accredited in Internal Medicine
and Clinical Pharmacology. Following a career in Clinical
and Academic Medicine and publishing widely on asthma,
inflammation and cough he joined Glaxo (now GlaxoSmithKline
(GSK)) as head of the Respiratory Clinical group.
He had several head positions within GSK, including
the Respiratory Therapeutic to manage both the development
matrix and the central clinical and commercial activities.
Subsequent to his position in GSK, Dr. Fuller joined
the Wellcome Trust as an executive board member for
Science Funding and worked as an independent consultant.
Dr. Fuller received a B.Sc. in Immunology from University
College London, his MB BS (MD) from St. Georges Hospital
Medical School London and his MD (Ph.D.) from the
University of London.
back to
the top
David A. Happel – Executive Vice President, Chief Commercial Officer
Previous Organizations: Chiron, InterMune, Parke-Davis/Pfizer
Previous Products: Accupril®, TOBI®, Actimmune®
Mr. Happel joins Aerovance with over 20 years of experience in the healthcare industry where he has held a number of senior commercial positions. Most recently he served as Vice President of Chiron’s pulmonary business unit where he worked the past four years. In his roles with Chiron and InterMune, Mr. Happel was responsible for the companies’ marketed and pipeline respiratory portfolios, including inhaled solution and dry-powder molecules for cystic fibrosis and lung transplantation. He started his career and worked for 15 years with Parke-Davis/Pfizer in sales, and in domestic and international marketing roles. He earned his master’s degree in business administration from Indiana State University and received his bachelor’s degree in chemistry from Indiana University. Mr. Happel also serves on the Board of Directors for the Boomer Esiason Foundation, an organization dedicated to finding a cure for cystic fibrosis.
back to
the top
Robert W.
Kuhn, Ph.D. – Senior Vice President, Chief Technology Officer
Previous Organizations: Bayer, Hana Biologics,
UCSF
Previous Products: Kogenate®, Trasylol®
Following post-doctoral studies in the area
of mechanism of steroid hormone action at Baylor College
of Medicine, Dr. Kuhn joined the faculty of the Reproductive
Endocrinology Center in the Obstetrics and Gynecology
Department at the University of California, San Francisco.
From 1975 to 1990, he performed research into the
mechanism of steroid hormone action and protein-steroid
interactions. From 1990 to 1993, he served as Director
of Biochemistry at Hana Biologics, which later merged
with Somatix Therapy Corporation. He joined Bayer
Corporation in 1993 became Director of Biochemistry
in 1995 and, in 1999, was appointed Vice President
of Process Sciences where he was responsible for a
department of 140 scientists and 15 contractors. Dr.
Kuhn spearheaded the process development of the second
generation of Kogenate, which entered the market in
2000. Dr. Kuhn received B.Sc. Degrees in Chemistry
and Biochemistry from Washington State University
and his doctorate in Biochemistry from the University
of Washington (Seattle).
back to
the top
Anthony M. Rimac, C.P.A.-- Vice President, Chief Financial Officer
Previous Organizations: Aradigm, Aesculap, Artemis Medical
Previous Products: MammoMark®, CorMark®, SkiPole Needle ®
Mr. Rimac joined Aerovance from Artemis Medical, Inc. where he led the sale of the Company to Johnson & Johnson in 2004. While at Artemis he served as the Vice President – Finance, and was involved in a number of Private Equity and Debt financings. Prior to his career at Artemis, he was Vice President – Finance & Administration at Aesculap, Inc., a division of the B|Braun Group of Companies. During his tenure at Aesculap, Mr. Rimac was responsible for all Finance, Information Technology and Facilities functions of the Company. He also has served as the Director of Financial Planning & Analysis for Aradigm Corporation, a public-traded Drug Delivery Company. Mr. Rimac holds a B.A. in Business Economics from the University of California at Santa Barbara, and an M.B.A. from Santa Clara University. Mr. Rimac also is a Certified Public Accountant licensed in the State of California.
back to
the top
